Mountain View, California, United States
+25 years in therapeutic product development in public (Genentech/Roche, Shire/Takeda) and private companies (SARcode Biosciences, ForSight VISION5, Graybug Vision); small molecules, biologics, sustained-release, drug delivery; ocular surface, glaucoma, retinal diseases and collagen-based medical devices..
Eluminex Biosciences is a privately-held clinical-stage biotechnology company focused on both global and regional development and commercialization of innovative therapeutics to fulfill unmet medical needs in the treatment and management of vision-threatening diseases.
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company committed to changing the treatment paradigm for high-risk pregnancy (preeclampsia, fetal growth restriction), acute ischemic stroke (AIS) and chronic kidney disease (CKD). DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of preeclampsia, acute ischemic stroke and chronic kidney disease.
Development of minimally invasive endovascular treatments for venous disease and complex aortic dissection and thoracic aneurysm repair. Fellowship Program Director.
Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
(Acquired by Allergan for $95M plus milestones) Sustained-delivery of bimatoprost using a novel ocular insert for the treatment of glaucoma/ocular hypertension. Phase 1, 2 development programs and Phase 3 planning. Development of fixed combination (bimatoprost/timolol) ocular insert for glaucoma/ocular hypertension.